{"news_desk": "Business", "print_page": "5", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By STEVEN DAVIDOFF SOLOMON", "person": [{"middlename": "Davidoff", "firstname": "Steven", "lastname": "SOLOMON", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": "Steven Davidoff Solomon Deal Professor column points to $152 billion deal between Pfizer and Allergan as prime example of inane deals that business executives seem intent on making at end of 2015; notes deal, much like Mylan's $26 billion takeover bid for Perrigo, underscores strangeness of United States corporate tax policy and part of range of evidence of end-of-year oddities among business executives.", "type_of_material": "News", "word_count": "1201", "lead_paragraph": "Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy.", "pub_date": "2015-11-25T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Pfizer-Allergan Merger Is Latest Sign of Deal Makers\u2019 Silly Pills", "content_kicker": "Deal Professor", "print_headline": "Telltale Signs That Deal Makers Swallowed the Silly Pills ", "kicker": "Deal Professor"}, "snippet": "Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy.", "multimedia": [{"height": 126, "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 600, "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "600", "xlarge": "images/2015/11/25/business/25DEALPROF/25DEALPROF-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/25/business/dealbook/telltale-signs-that-deal-makers-swallowed-the-silly-pills.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Corporate Taxes", "name": "subject"}, {"rank": "11", "is_major": "N", "value": "Taxation", "name": "subject"}, {"rank": "12", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "13", "is_major": "N", "value": "Coury, Robert J", "name": "persons"}, {"rank": "2", "is_major": "Y", "value": "Allergan Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Mylan Inc", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Perrigo Company", "name": "organizations"}, {"rank": "5", "is_major": "Y", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "6", "is_major": "Y", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Pershing Square Capital Management", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "Ackman, William A", "name": "persons"}, {"rank": "9", "is_major": "N", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "10", "is_major": "N", "value": "Herbalife Ltd", "name": "organizations"}], "blog": [], "_id": "565506d038f0d80209d5af07", "source": "The New York Times"}